Therapeutic Outcomes on Il-17 Levels With Cd20 Versus Tnf-α Inhibitors in Rheumatoid Arthritis
Year: 2025
Type: article
Abstract: Back ground: Rheumatoid arthritis (RA) is a chronic , systemic , inflammatory disorder that may affect many tissues and organs ,once a diagnosis is made , the main treatment goals are to control disease activity and slow the rate of joint damage ,in addition to minimizing pain, stiffness, inflammation and complications. Important role of IL-17 in the development of disease and can be used as a marker for monitoring of disease activity. Aim of the Study The aim of the present study to evaluate the effects of CD20 inhibitors therapy in comparison to effects of TNF α inhibitors therapy on IL-17 in patients with active rheumatoid arthritis. Results:- results obtained in the present study showed that serum level of IL-17were also decrease significantly in patients treated with Rituximab group 3 ( 2.28 ) than those of group 2 Etanercept (anti-TNFα) treate d group patients (3.3). Conclusion: - the role of IL-17 in the development of disease and can be used as a marker for monitoring of disease activity
Author: Hussein, Nabeel Al-Hashimi
Institution: University of Baghdad
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7101699166
FWCI:
Cites:
Cited by:
Related to: